Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

SLU-PP-332 cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established SLU-PP-332 cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. No human studies; no duration of human use has been studied 7.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • SLU-PP-332 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established SLU-PP-332 cycle length?
No. Human studies administered SLU-PP-332 for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of SLU-PP-332?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
SLU-PP-332 dosing reference Full research page

References

  1. Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity ACS Chem Biol. 2023
  2. A Synthetic ERR Agonist Alleviates Metabolic Syndrome J Pharmacol Exp Ther. 2024
  3. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function Circulation. 2024
  4. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney Am J Pathol. 2023
  5. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study Front Physiol. 2025
  6. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential Rapid Commun Mass Spectrom. 2026
  7. ClinicalTrials.gov API search for SLU-PP-332 (no registered studies returned on 23 October 2026) ClinicalTrials.gov. 2026
  8. Drugs@FDA application data queried through openFDA for SLU-PP-332 (no matching application record returned on 23 October 2026) openFDA / Drugs@FDA. 2026
  9. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1, 2 and 3; updated May 14, 2026) FDA. 2026
  10. PubChem compound record for SLU-PP-332 (CID 5338394; CAS 303760-60-3) PubChem. 2026
  11. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026